JNJ-78934804 for Crohn's Disease

(DUET ENCORE-CD Trial)

This trial tests two treatments, JNJ-78934804 (an experimental treatment) and guselkumab, to evaluate their effectiveness and safety for people with Crohn's disease, a long-term condition causing inflammation in the intestines. Participants will receive one of the treatments and be monitored over 48 weeks to compare effectiveness. The trial seeks individuals who have had Crohn's disease for at least 12 weeks, experience frequent diarrhea or abdominal pain, and have not responded well to other treatments. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to the potential availability of new treatments for Crohn's disease.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

A previous study found JNJ-78934804 to be safe, with patients experiencing higher rates of clinical remission and generally tolerating the treatment well. Serious infections occurred rarely. Another study confirmed that JNJ-78934804's safety profile is similar to other treatments of its kind.

Research on guselkumab has shown it to be safe and effective for Crohn's disease. Most patients did not experience new or unexpected side effects. Reports suggest it is well-tolerated, with no major safety concerns.

Researchers are excited about JNJ-78934804 for Crohn's Disease because it represents a fresh approach compared to existing treatments. While current therapies like biologics often target tumor necrosis factor (TNF), JNJ-78934804 is designed to work differently by focusing on another pathway potentially involved in inflammation. This could provide an option for patients who don't respond well to standard treatments. Additionally, guselkumab, used as an active comparator in the trial, is already known for effectively targeting the interleukin-23 (IL-23) pathway, adding another layer of potential benefit in managing Crohn's Disease. These innovative mechanisms offer hope for improved symptom relief and disease management.

Research has shown that JNJ-78934804, one of the treatments studied in this trial, holds promise for treating Crohn's disease. In one study, 50.8% of patients experienced significant symptom improvement, known as clinical remission. For improvements observed inside the intestines through a scope, called endoscopic response, the rate was 38.1%. These results surpassed those from other treatments like golimumab. Another study found that JNJ-78934804 nearly doubled the clinical remission rates compared to other treatments. This suggests that JNJ-78934804 could be a strong option for people with Crohn's disease who haven't had success with other treatments. Participants in this trial may receive JNJ-78934804 or Guselkumab, another treatment option under evaluation.⁶⁷⁸⁹¹⁰